Revised SPCs: Ibrance (palbociclib) hard capsules – all strengths

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
25 November 2019

Abstract

Interstitial lung disease and/or pneumonitis added as adverse effects of treatment based on pooled dataset from 3 randomised studies; together with relevant discontinuation recommendations. The median duration of palbociclib treatment across the pooled dataset was 12.7 months.